Cover Image

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97...

Full description

Saved in:
Bibliographic Details
Main Authors: Kayser, Sabine (Author) , Martínez-Cuadrón, David (Author) , Hanoun, Maher (Author) , Stölzel, Friedrich (Author) , Gil, Cristina (Author) , Reinhardt, H. Christian (Author) , Aguiar, Eliana (Author) , Schäfer-Eckart, Kerstin (Author) , Burgues, Juan Miguel Bergua (Author) , Steffen, Björn (Author) , Bernal, Teresa (Author) , Krause, Stefan W. (Author) , Riaza, Rosalía (Author) , Schliemann, Christoph (Author) , Cervera, Jose (Author) , Kaufmann, Martin (Author) , Torres-Miñana, Laura (Author) , Hänel, Mathias (Author) , Acuña-Cruz, Evelyn (Author) , Jost, Edgar (Author) , Algarra, Jesus Lorenzo (Author) , Crysandt, Martina (Author) , Fransecky, Lars (Author) , Cornago-Navascues, Javier (Author) , Kraus, Sabrina (Author) , Martinez-Lopez, Joaquin (Author) , Einsele, Hermann (Author) , Niemann, Dirk (Author) , Neubauer, Andreas (Author) , Seggewiß-Bernhardt, Ruth (Author) , Scholl, Sebastian (Author) , Klein, Stefan (Author) , Schmid, Christoph (Author) , Schaich, Markus (Author) , Schmidt-Hieber, Martin (Author) , Zukunft, Sven (Author) , Ho, Anthony Dick (Author) , Platzbecker, Uwe (Author) , Baldus, Claudia D. (Author) , Müller-Tidow, Carsten (Author) , Thiede, Christian (Author) , Bornhäuser, Martin (Author) , Serve, Hubert (Author) , Levis, Mark (Author) , Montesinos, Pau (Author) , Röllig, Christoph (Author) , Schlenk, Richard Friedrich (Author)
Format: Article (Journal)
Language:English
Published: January, 2023
In: Haematologica
Year: 2023, Volume: 108, Issue: 1, Pages: 34-41
ISSN:1592-8721
DOI:10.3324/haematol.2022.281137
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2022.281137
Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/haematol.2022.281137
Get full text
Author Notes:Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schäfer-Eckart, Juan Miguel Bergua Burgues, Björn Steffen, Teresa Bernal, Stefan W. Krause, Rosalía Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Miñana, Mathias Hänel, Evelyn Acuña-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiß-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Hubert Serve, Mark Levis, Pau Montesinos, Christoph Röllig and Richard F. Schlenk
Description
Summary:We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients had double CEBPA mutations. Data on response to intensive anthracycline-based induction therapy were available for 119 patients. Complete remission was achieved in 67% (n=80) and the early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a complete remission rate of 89%. Allogeneic hematopoietic cell transplantation was performed in 40 (34%) patients, of whom 19 were transplanted in first complete remission. The median follow-up of the intensively treated cohort was 5.76 years (95% confidence interval [95% CI]: 2.99-7.61 years). The 5-year overall survival and relapse-free survival rates were 30% (95% CI: 22-41%) and 27% (95% CI: 18-41%), respectively. An Andersen-Gill regression model on overall survival revealed that favorable-risk according to the European LeukemiaNet classification (hazard ratio [HR]=0.34; P=0.006) and trisomy 4 as sole abnormality (HR=0.41; P=0.01) were favorable factors, whereas age with a difference of 10 years (HR=1.15; P=0.11), female gender (HR=0.74; P=0.20) and allogeneic hematopoietic cell transplantation (HR=0.64; P=0.14) did not have an significant impact. In our cohort, patients with trisomy 4 as their sole abnormality had a high complete remission rate and favorable clinical outcome. Allogeneic hematopoietic cell transplantation did not seem to improve overall survival.
Item Description:Zuerst veröffentlicht: 9. Juni 2022
Gesehen am 16.08.2023
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2022.281137

Similar Items